The Swedish Economic Crime Authority terminates the investigation of Oncopeptide’s Chief Scientific Officer Jakob Lindberg
Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, has been informed that the preliminary investigation by the Swedish Economic Crime Authority of the company’s Chief Scientific Officer and former CEO has been terminated.
In their decision, the Swedish Economic Crime Authority writes that there is no longer a reason to complete the preliminary investigation as "the investigative material available [does not] prove that the person or persons who were suspected have committed any crime."
"We are pleased to see that the Swedish Economic Crime Authority has found no reason to pursue its preliminary investigation further. We have fully collaborated with the Swedish Economic Crime Authority throughout this investigation and have also supported our CSO in this challenging situation,” says Monica Shaw, CEO Oncopeptides. “Our confidence in Jakob Lindberg is absolute and unchanged, and we highly value his contribution to Oncopeptides.”